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A B S T R A C T
Objective of this study was to assess platelet response to clopidogrel and its association with certain single nucleotide
polymorphisms (SNPs) of the P2RY12 gene. Several studies have shown that patients with poor in vitro response to
clopidogrel have worse outcomes after coronary interventions. Pharmacological response to clopidogrel is mediated by
the P2Y12 platelet receptor, therefore, SNPs of the P2RY12 gene may account for some of the observed variability in the
cardiovascular risk. Fifty patients with stable coronary heart disease, undergoing percutaneous coronary intervention
were included in this study. Response to clopidogrel was analysed using light transmitted aggregometry before, and 5
days after the initation of therapy. SNPs analysed: c.–15+742C>T, c.–180+2739T>C and c.18C>T. A higher propor-
tion of non-responders to clopidogrel were noted in carriers of 18C>T[T/T] (p=0.05), and lower prevalence in carriers of
742C>T[T/T] (p=0.05). Participants with 742C>T[T/T] had significantly higher change in aggregation compared to
other 742C>T variants ([C/C]=20.5±21.9%; [C/T]=20.0±31.2%; [T/T]=48.6±21.3%; p=0.03). Those carrying 18C>
T[T/T] had smaller change in aggregation (7.6±15.0%) compared to other variants, but the difference was not statisti-
cally significant (p=0.15). Analysis of variance showed 18C>T[T/T] was a statistically significant predictor of poor re-
sponse to antiaggregation therapy, independent from other clinical and demographic variables. There was no relation
between poor response to clopidogrel and any other genetic variant. Our results suggest that 18C>T SNP of the P2RY12
gene may be an independent predictor of pharmacological response to clopidogrel. Larger prospective studies are needed
to confirm this link and assess its possible clinical consequences.
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gene, antiplatelet therapy
Introduction
Platelet activation and aggregation is involved in the
progression of the atherosclerotic vascular disease by
triggering acute adverse events such as acute coronary
syndrome (ACS) and stroke1. The adenosine diphosphate
(ADP) P2Y12 receptor plays a critical role in platelet
activation2. This is the rationale for the use of P2Y12 re-
ceptor antagonist clopidogrel in treatment of ACS and
secondary prevention of cardiovascular (CV) events. Clo-
pidogrel has been associated with a significant reduction
in the combined risk of ischaemic stroke, myocardial in-
farction, or vascular death in population of patients with
recent ischaemic stroke, recent myocardial infarction or
symptomatic peripheral arterial disease3. However, car-
diovascular events may still occur in patients treated
with percutaneous coronary intervention (PCI) despite
the use of clopidogrel. Stent thrombosis develops in 0.5–
2% of PCI treated patients, while death, myocardial in-
farction or stroke occur in 8.5% of them. Finally, 21.4% of
patients require revascularisation 1 year after PCI4,5.
Significant interindividual variability in response to clo-
pidogrel (prevalence of non-responders [change in plate-
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let aggregation £10%] ranges from 6% to 58%) may ex-
plain lack of protection in some of the treated indivi-
duals6. This is supported by recent studies that showed
an association between in vitro platelet reactivity follow-
ing administration of clopidogrel and the risk of new CV
events after PCI7–9.
There are a number of mechanisms that are involved
in modulation of the clopidogrel effect on the P2Y12 re-
ceptor, including variability in absorption, blood concen-
tration of its active metabolite, or drug-drug interac-
tions10. Resistance to clopidogrel may be determined by
interindividual differences in number or activity of P2Y12
receptors, cellular capacity to release ADP, or platelet ac-
tivation via alternative pathways11. These mechanisms
may be associated with genetic factors12.
Several studies have analysed single nucleotide poly-
morphisms (SNP) of P2RY12 gene in order to assess
their association with clinical CV outcomes or with the
effect of clopidogrel on platelet function. It has been re-
ported that in certain populations 742C>T is predictive
of the peripheral arterial disease and platelet aggrega-
tion. In addition, 2739T>C was associated with the risk
of stent restenosis and with response to administration
of clopidogrel and 18C>T may be predictive of the risk
for neurological events and showed an association tenden-
cy of increase in ADP-induced platelet aggregation13–18.
In this study we assessed the effect of clopidogrel on
platelet aggregability and whether the platelet response
to clopidogrel associates with certain SNPs of several
P2RY12 gene loci in a group of individuals with angio-




Fifty patients with stable coronary heart disease were
included in the study. All participants had previously un-
dergone coronary angiography, were diagnosed with sig-
nificant coronary artery obstruction (defined as coronary
artery stenosis >50%) and were scheduled for PCI. In ad-
dition to angiographically confirmed stable coronary heart
disease, participants must have been between 18 and 80
years old. Those who met one or more of the following
criteria were excluded from the study: acute bleeding,
acute coronary syndrome, stroke within last 3 months,
prothrombin time (PT) >1.5, platelet count <100,000/
mm3, hematocrit <0.25, creatinine >177 mmol/dm3,
and/or continuous thienopyridine therapy before the en-
try visit. Patients were recruited between November of
2007 to March of 2009. The study was approved by the
Institutional Ethics Review Board of the University Hos-
pital »Sveti Duh« in accordance with the Declaration of
Helsinki. Written informed consent was obtained from
each participant.
Study design
After signing the informed consent patients were hos-
pitalized, medical history was taken and physical exam
was performed. Blood samples were obtained for hemato-
logical and biochemical tests, platelet aggregometry and
genotyping. Patients were then administered the loading
dose of clopidogrel (300 mg), followed by the mainte-
nance dose (75 mg per day). PCI was performed the fol-
lowing day. All patients received 100 IU/kg of heparin
intracoronary during the intervention folowed by 100 mg
of aspirin daily. Five (5) days (±1 day) after administer-
ing loading dose of clopidogrel blood samples were ob-
tained for post-treatment aggregometry measurement.
Aggregometry
Blood samples for aggregometry were collected in
tubes containing 3.2% citrate. Light transmitted (turbi-
dimetric) aggregometry (LTA) was performed in platelet-
-rich plasma (PRP) with a platelet count adjusted to
(250 25) ´ 109/dm3. Platelets were stimulated with 5 mM
ADP. Aggregation was performed with Behring Coagula-
tion Timer (BCT) (Dade Behring, Frankfurt, Germany).
Aggregation was expressed as the maximal percentage
change in light transmittance from baseline with plate-
let-poor plasma (PPP) as reference. Normal response to
clopidogrel was defined as the difference (reduction) be-
tween baseline and post-treatment aggregometry mea-
surement of more than 10%, while response ?10% was
considered as indicating the lack of normal response
(„non-responders«), as previously described19. Standard
deviation for repeated intraindividal measurements was
previosly obtained and used as an estimate of variability
for this method. It ranged from 3.6 to 7.7%, with day-to-
-day variation accounting for the majority of the varia-
tion, followed by operator variability20.
Genotyping
Deoxyribonucleic acid (DNA) extraction from blood
samples was performed using BIOROBOT EZ1 and EZ1
DNA blood extraction kit (Qiagen, USA) according to the
manufacturer’s instructions. Real-Time polymerase chain
reaction (PCR) SNP analysis of three SNPs was per-
formed using an ABI PRISM 7000 Sequence Detection
System (Applied Biosystems, USA) and predeveloped
TaqMan SNP genotyping assay reagents for three
P2RY12 SNPs: rs2046934 (c.–15+742C>T), rs6787801
(c.–180+2739T>C) and rs6785930 (c.18C>T) (Applied
Biosystems, USA). 742C>T SNP genotyping was used to
tag the H1(742T) and H2 (742C) haplotypes14. Annota-
tion of the selected SNPs is according to the nomencla-
ture recommendations of the Human Genome Variation
Society, using the cDNA sequence available under Gen-
Bank accession number NM_022788.3 as reference. PCR
was carried out according to the manufacturer’s proto-
col. Control samples covering three possible SNP geno-
types for each SNP and no template control were run in
parallel with tested samples in each experiment.
Other laboratory analyses
Routine laboratory analysis included complete blood
count (analysis done on Sysmex XE 2100, Sysmex Amer-
ica, Inc., Mundelein, IL, USA); potassium, sodium, urea,










creatinine, serum glucose, aspartate transaminase, ala-
nin transaminase, gamma-glutamyltransferase, uric acid,
total cholesterol, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, triglycerides (testing
performed using Olympus AU 400, Olympus, Mishima,
Japan); prothrombine time, international normalized ra-
tio, activated partial thromboplastin time and fibrinogen
(measured on Siemens BCS-XP Siemens Healthcare Di-
agnostics, Deerfield, IL, USA). The coefficient of varia-
tion for fibrinogen was 2.9% and 7.2% within series for
Control Plasma N and Control Plasma P, respectively.
From day to day it was 1.6% and 3.4%.
Statistical analysis
The sample size for the study was defined based on
the frequency of inidividual polimorphisms as described
in the literature in a population similar to ours. Data re-
ported by Fontana et al. indicate that at least 40 subjects
from the Caucasian population should be sufficient to
identify polymorphisms with frequency of 5% with a con-
fidence interval (CI) of 95%13. Hardy-Weinberg equilib-
rium of genotype frequency was tested using Chi-square
test. All SNP’s genotype frequencies were in agreement
with the Hardy-Weinberg equilibrium.
Descriptive statistics included means and standard
deviation for continuous variables and counts and pro-
portions (percentages) for categorical variables. Respon-
se to clopidogrel was calculated by subtracting baseline
% aggregation from the measure of aggregation obtained
at endpoint (after 5 days). ANOVA was used to test con-
tinuous variables and Fisher’s test for categorial vari-
ables.
Analysis of variance was used to assess interaction be-
tween genetic and nongenetic factors to assess potential
mechanisms responsible for differences in response to
clopidogrel. The following categorical variables were in-
cluded in the initial assessment: genotypes of each SNP
(major variant homozygote, heterozygote, minor variant
homozygote), gender, diabetes, smoking, hypertension,
hyperlipidemia, previous myocardial infarction, previous
stroke, previous PCI, previous CV event, statins, beta
blockers, ACE inhibitors or Angiotensin receptor blo-
ckers (ARBs). The following continuous variables were
also included: body mass index (BMI), high density lipo-
protein cholesterol (HDL), fibrinogen and % aggregation
after stimulation with epinephrine. The following vari-
ables were statistically significant with respect to the
change in clopidogrel, as measured by change in platelet
aggregation after 5-day tretament with clopidogrel: SNP
742C>T, SNP 18C>T, fibrinogen level, and previous
PCI. There was a statistically significant correlation be-
tween the genotypes of SNPs 742C>T and 18C>T. For
this reason and because of opposite effects of the homo-
zygote genotypes of these SNPs (18T homozygote group
was associated with poor response and 742C homozygote
group had greater response to clopidogrel than the aver-
age), the final model excluded 742C>T to focus on 18C>
T due to its potentially greater value in detecting individ-
uals at higher risk of poor response and subsequent new
CV events.
Statistical analysis was performed using the Statisti-
cal Analysis Systems, version 9.2, software (SAS Insti-
tute, Cary, North Carolina, USA).
Results
Patient disposition
Table 1 shows summary demographic and clinical
characteristics of 50 individuals included in the study.
The study population had a high prevalence of CV risk
factors, including hypertension, hyperlipidemia, and used
CV medications frequently, as expected in people with
coronary heart disease (CHD). Approximately 26% of
them had diabetes. All participants completed all proce-
dures at baseline and the follow up visit, as planned.
Platelet aggregation and response to clopidogrel
Mean baseline (±SD) platelet aggregation for the
overall group was 63.22±14.60%. One patient had low
(<19%) aggregation before the initiation of clopidogrel.
Figure 1A shows distribution of platelet aggregation data
at baseline. Five days after the initiation of therapy with










LDL cholesterol (mmol/dm3) 3.05±1.14
HDL cholesterol (mmol/dm3) 1.35±0.31
Triglicerides (mmol/dm3) 2.32±1.47
Fibrinogen (g/dm3) 4.49±1.08
Prothrombine time (s) 104.4±14.67
APTT (s) 27.12±4.02
Male/Female 35/15 70/30
Obesity (Y/N) 42/8 84/16
Diabetes (Y/N) 13/37 26/74
Smoking (Y/N) 10/40 20/80
Hypertension (Y/N) 43/7 86/14
Hyperlipoproteinaemia (Y/N) 46/8 92/8
Statin therapy (Y/N) 45/5 90/10
Beta-blocker therapy (Y/N) 31/19 62/38
ACE inhibitor/ ARBs therapy (Y/N) 42/8 84/16
BMI = body mass index, LDL = low density lipoprotein, HDL =
high density lipoprotein, APTT = activated partial thrombo-










clopidogrel mean (±SD) platelet aggregation was 38.26±
17.75%, with an average decrease of 23.18±23.32%. Fig-
ure 1B shows distribution of response to clopidogrel ad-
ministration (after stimulation with 5 mM ADP) 5 days
after the initiation of therapy. Fourteen individuals
(28%) out of 50 who participated in the study met the cri-
terion for resistance to clopidogrel (decrease in platelet
aggregation £10%, mean change in aggregation±SD
–3.71±13.60%).
Assessment of single nucleotide polymorphisms
of the P2RY12 gene
Distribution of various SNPs for all three single loci of
the P2RY12 gene analyzed (742C>T, 2739T>C, 18C>T)
are shown in Table 2. For each category within an indi-
vidual SNP a proportion of poor responders was ana-
lyzed. This data is presented in Table 3. In most of the
subgroups suppression of platelet aggregation was bet-
ween 20 and 30%. Only two out of 9 subgroups were sig-
nificantly different from other subgroups within indi-
vidual SNPs. In the minor variant homozygote (T/T) sub-
group of 742C>T, which included 5 participants, there
were no poor responders (p=0.05 for within the SNP
comparison). In the minor variant homozygote (T/T)
subgroup of 18C>T a high proportion of non-responders
was observed (42.9%) (p=0.05 for within the SNP com-
parison). Three out of 7 participants from this subgroup
had a suppression of initial platelet aggregability £10%
(mean change in aggregation±SD was –5.67±13.61).
These results indicated a possibility that the two forms of
homozygote variations of the P2RY12 gene may be hav-
ing the opposite effect on platelet aggregation. Figure 2
shows graphically the effect of clopidogrel therapy on
platelet aggregation as measured by LTA for each genetic
variant of each of the SNPs included in the study.
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Fig. 1. A) Distribution of platelet aggregation data at baseline; B)
Distribution of response to clopidogrel 5 days after the initiation
of therapy.
TABLE 2








adjustright n 34 11 5
% poor response 32.4 27.3 0 0.05
Mean Ä aggregation ± SD 20.5 ± 21.9 20.0 ± 31.2 48.6 ± 21.3 0.03
2739T>C
n 14 20 16
% poor response 28.6 30 25 0.07
Mean Ä aggregation ± SD 27.9 ± 30.6 18.0 ± 20.6 25.5 ± 19.1 0.43
18C>T
n 24 19 7
% poor response 25 26.3 42.9 0.05
Mean Ä aggregation ± SD 24.7 ± 24.7 26.9 ± 22.7 7.6 ± 15.0 0.15










Relationship between platelet aggregation and
SNPs of the P2RY12 gene (ANOVA)
Initial analyisis of variance model included the re-
sponse to clopidogrel as dependent variable and genetic
SNP variants, significant pre-existing conditions (abnor-
malities associated with increased CV risk, previous CV
outcomes), and CV medications and laboratory measure-
ments (HDL cholesterol, fibrinogen) as independent va-
riables. In this model the strongest relationship was
found between the response to clopidogrel and 742C>T,
18C>T, history of previous PCI, and concentration of
fibrinogen. As described above, patients with minor ho-
mozygote variant 742C>T (T/T) displayed tendency to-
wards greater than average response to clopidogrel and
no resistance. Patients with minor homozygote variant
of the 18C>T had a response that suggested a poorer re-
sponse as compared to other variants of the same locus,
as well, as other loci (Table 2). There was also an in-
creased association between these minor homozygote
variants of 742C>T and 18C>T, unabling definite sepa-
ration of the effect of these two genetic variants on
platelet activity. For these reasons and because of the
previously reported data indicating lack of association
between 742C>T and CV risk, the final analysis model
excluded 742C>T polimorfisms. The final model showed
that variants of 18C>T were the best predictor of inade-
quate platelet response to clopidogrel, independent from
other variables that were included in this final analysis
because of their statistically significant association with
the response to clopidogrel in the primary assessment
(fibrinogen and history of previous PCI).
Discussion
In this study we assesed possible relationship be-
tween the platelet response to clopidogrel administration
and single nucleotide polymorphisms of its target recep-
tor gene P2RY12 in patients with stable coronary artery
disease undergoing elective coronary stenting. Increased
prevalence of poor response to clopidogrel was associated
with rs6785930 (18C>T) minor variant homozygous ge-
notype (T/T). This relationship could not be explained by
any other factor clinical or demographic, including those
that showed strong association with the change in pla-
telet aggregation during the therapy (fibrinogen, previ-
ous PCI). Since this was an exploratory study, with small
number of participants included, these results should be
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TABLE 3
NUMBER OF POOR RESPONDERS TO CLOPIDOGREL IN EACH GENOTYPE CATEGORY OF THREE P2RY12 GENE SINGLE
NUCLEOTIDE POLYMORPHISMS
SNP 742C>T 2739T>C 18C>T
Genotype C/C C/T T/T T/T T/C C/C C/C T/C T/T
Patients (n) 34 11 5 14 20 16 24 19 7
Response >10% £10% >10% 10% >10% £10% >10% £10% >10% £10% >10% £10% >10% £10% >10% £10% >10% £10%
Patients (n) 23 11 8 3 5 0 10 4 14 6 12 4 18 6 14 5 4 3
Fig. 2. Effect of clopidogrel therapy on platelet aggregation for









re-evaluated in a larger population using longitudinal
follow up to include CV outcome data.
The study population encompassed a homogenous
group of patients with stable coronary heart disease un-
dergoing PCI. This population is commonly included in
studies that assess genetic factors involved in the pato-
physiology of CV disease. These individuals are often
treated with clopidogrel and understanding the effect of
this drug on the platelet function and CV risk in this
high-risk population is of clinical importance. As descri-
bed in the Results section of this report, 28% of partici-
pants were non-responders to clopidogrel. This result
was obtained using the light transmission aggregometry
methodology, the gold standard method for platelet func-
tion testing19. To increase the accuracy of the platelet
functional estimate, baseline and on-treatment measure-
ments were obtained as is mandatory due to high inter-
individual variability in platelet reactivity and in labora-
tory test responses21,22. The obtained proportion of non-
-responders is in the middle of the frequency range re-
ported in the literature19,23–25.
18C>T minor variant homozygous genotype (T/T)
was associated with increased prevalence of individuals
with poor response to clopidogrel in the study popula-
tion, although no difference between the variants of this
locus was observed in the magnitude of the response.
This may be explained by small number of individuals in
many of the subgroups and relatively high variability of
the platelet aggregation. In the initial ANOVA models we
found that additional factors were statistically signifi-
cantly associated with the effect of clopidogrel on platelet
aggregation, namely, concentration of fibrinogen, previ-
ous PCI and 742C>T polymorphism. Since 742C>T mi-
nor allele polymorphism had an opposite effect (increa-
sed response to clopidogrel) it was excluded from the
final model which focused on variables predictive of poor
response to clopidogrel. This final model indicated that
variants of 18C>T were the best predictor of the platelet
response to clopidogrel, independent from fibrinogen or
history of previous PCI. In a study of P2RY12 SNP
18C>T by Fontana et al. no association between platelet
aggregation and 18C>T polymorphism was observed14.
In two studies of relationship between this SNP and clin-
ical outcomes, Zee et al. reported no evidence of associa-
tion with incident MI, ischemic stroke or DVT/PE25, but
Ziegler et al. reported that patients carriers of 18C>T
had four-fold increased adjusted risk for neurological
events despite therapy with clopidogrel17. Recently, Lee
et al. reported that haplotype which contains 18C>T
SNP showed an association tendency with 7% increase in
ADP-induced platelet aggregation in healthy subjects
when compared to individuals with the reference haplo-
type18.
NCBI SNP database (dbSNP) currently has more
than 200 listed SNPs in the region of P2RY12 gene which
contains three exons, of which only exon 3 is coding.
Even though 18C>T is positioned in exon 3, the change
in nucleotides does not change the code for the amino-
-acid in that particular codone (asparagine). It is possible
that 18C>T is a part of a haplotype that interferes with
gene regulation within the P2RY12 coding region, which
may have an effect on P2Y12 receptor and consequently
on platelet’s response to clopidogrel.
The other two SNPs assessed in the study population
(742C>T and 2739T>C) were already investigated in
several populations. In our study patients who carry
742C>T minor variant polymorphism (T/T) (homozy-
gotes) all responded well to clopidogrel therapy which is
in agreement with the most of the recent reports, al-
though most recent report from Lee et al. showed signifi-
cant 8% increase in ADP-induced platelet aggregation in
healthy male individuals carrying haplotype containing
minor variant of 742C>T polymorphism compared with
reference haplotype.18 Rude` et al. initially reported that
P2RY12 SNPs 2739T>C may be associated with altered
ADP-mediated platelet aggregation and risk of arterial
thrombosis.27 In a subsequent report the same group sug-
gested that 2739T>C predicts the risk of restenosis in
patients treated with PCI and stenting. Results of a large
cross-sectional study report that 2739T>C polymor-
phism is responsible for most of the haplotype effects on
the action of clopidogrel on platelet aggregation. We
found no significant difference in clopidogrel response
regarding 2739T>C SNP in our population. The reason
for this discrepancy may relate to different methodologi-
cal approaches between the two studies. In their study
(n=1031) Rude` et al. performed a single assessment of
the platelet function after the initiation of treatment
with clopidogrel (»on-treatment«) using LTA and Verify-
Now P2Y12 assays. As mentioned before, intraindividual
variability in platelet reactivity makes single-point-in-
-time tests in assessing the response to antiplatelet ther-
apy less accurate as compared to multiple intraindividual
measurements, which may be the reason for discrepancy
from our results15,16. Most recent study from the same
group reported that carriers of minor variant of 2739T>C
polymorphism have increased response to cangrelor –
novel irreversible P2Y12 inhibitor28.
Further studies, involving more P2RY12 SNPs and
evaluation of major and minor haplotypes in regards to
standardized tests of the response to antiplatelet therapy
are warranted to provide more accurate perspective on
genetic determinants in patients with suboptimal re-
sponse to agents that target P2Y12 receptor.
There are several limitations of this study which in-
clude small study population and SNPs beeing analyzed.
Also there was no clinical follow-up regarding clinical
outcomes related to different platelet reactivity under
clopidogrel treatment. At the time this study was con-
ducted antiplatelet therapy guidelines advised a loading
dose of clopidogrel of 300 mg so no subsequent compari-
son of 300 mg and 600 mg loading dose of clopidogrel
could be done. In most previous similar studies diabetics
versus non-diabetics had lower response to antiplatelet
(clopidogrel) treatment. Our results have shown no sta-
tistical difference regarding response to clopidogrel be-
tween these two subgroups of patients.











Results of the study reported here suggest that 18C>T
single nucleotide polymorphism of the target receptor
gene P2RY12 is the best independent predictor of phar-
macological response to clopidogrel, but larger prospec-
tive studies are needed to confirm the suggested link of
18C>T P2RY12 SNP with response to clopidogrel and
possible clinical consequences that homozygotes of mi-
nor 18C>T allele might suffer.
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POLIMORFIZMI P2RY12 GENA I U^INAK KLOPIDOGRELA NA AGREGACIJU TROMBOCITA
S A @ E T A K
Cilj ovog istra`ivanja bio je procjena odgovora trombocita na klopidogrel i njegove povezanosti s odre|enim polimor-
fizmima jedne baze (single nucleotide polymorphism – SNP) P2RY12 gena. Nekoliko je studija pokazalo kako bolesnici
sa slabijim in vitro odgovorom na klopidogrel imaju lo{ije ishode nakon koronarnih intervencija. Farmakolo{ki odgovor
na klopidogrel posredovan je preko P2Y12 receptora, stoga bi SNP-ovi P2RY12 gena mogli biti odgovorni za dio primje-
}ene varijabilnosti u kardiovaskularnom riziku. U ovo istra`ivanje bilo je uklju~eno pedeset bolesnika sa stabilnom
koronarnom bole{}u predvi|enih za perkutanu koronarnu intervenciju. Odgovor na klopidogrel analiziran je metodom
svjetlosne agregometrije prije te 5 dana nakon zapo~ete terapije klopidogrelom. Analizirani SNP-ovi: : c.-15+742C>T,
c.-180+2739T>C and c.18C>T. Ve}a proporcija »lo{ih odgovara~a« na klopidogrel zabilje`ena je kod nositelja poli-
morfizma 18C>T[T/T] (p=0,05), a ni`a prevalencija kod nositelja 742C>T[T/T] (p=0,05). Ispitanici nosioci 742C>
T[T/T] imali su zna~ajnije ve}u promjenu u agregaciji trombocita u usporedbi s drugim varijantama 742C>T varijante










([C/C]=20,5±21,9%; [C/T]=20,0±31,2%; [T/T]=48,6±21,3%; p=0,03). Nosioci 18C>T[T/T] imali su manju promjenu u
agregaciji trombocita (7,6±15,0%) u usporedbi s drugim varijantama, ali razlika nije bila statisti~ki zna~ajna (p=0,15).
Analiza varijance pokazala je da je polimorfizam 18C>T[T/T] statisti~ki zna~ajan prediktor za slabi odgovor na anti-
agregacijsku terapiju, neovisan o drugim klini~kim i demografskim varijablama. Nismo otkrili drugu vezu izme|u sla-
bog odgovora na klopidogrel i neke druge istra`ivane geneti~ke varijante. Na{i rezultati ukazuju da bi 18C>T SNP
P2RY12 gena mogao biti nezavisni prediktor farmakolo{kog odgovora na klopidogrel. Potrebne su ve}e prospektivne
studije kako bi se potvrdila ova povezanost te kako bi se procjenile njene mogu}e klini~ke posljedice.
E. Gali} et al.: P2RY12 Gene and Platelet Aggregation, Coll. Antropol. 37 (2013) 2: 491–498
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